DNAY - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Quarter 3 2021 Codex DNA Inc. Earnings Conference Call. At this time, all participants’ lines are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator instructions] I would now like to turn the conference over to your host, Mr. Lepke. Richard ahead. go please Sir,

Richard Lepke

Chief you, Financial Mel. for With for us Jennifer Nelson, and today Chief Gibson, Technology Officer; Good DNA's third afternoon, and our Todd Codex are call. our the thanks Officer; quarter Dan on our Chief joining McNealey, call Thank Executive Officer. XXXX me earnings

third press release Investor website. our of quarter is the Our section available now on

release, list, or to If send if like the you have ir@codexdna.com. added distribution not to to the email news company's please received an be you'd

Before certain include or accurate we actual cause statement statements and in this call implied. be the begin, you release I as factors risks the would those earnings like expressed our filings is may Harbor conference These live statements SEC. call results on to inform in X, to This in forward-looking. and involve only that Safe unknown and information that during the XXXX. known included differ our contains November and of broadcast time-sensitive with we materially make referenced uncertainties those Such will from

Finally, otherwise With Codex I'd any on to will discussed to like over the noted. turn call DNA's that, basis year-over-year CEO. percentage Todd, changes a we unless be

Todd Nelson

recently the chapter of past quarter afternoon, solid strong Rich, Notably, for more in sales of driven for made help growth in royalty were was results by and and quarter execution. XX%. launched product revenue instruments drivers Codex revenue commercial terms XX%, This the also to focusing longer reagent R&D next our Thanks, transformational business build. franchise in story. variant more good of than everyone. another on BioXp share quarter and for BioXp growth contributions instrument record areas write kits revenue These sales of business and comprised results performance quarter. will three growth We from sustainable XXXX. as strategic third BioXp particularly our and libraries strong applications progress a both perspective development, the Sales kits of pleased a We're and complex our with had DNA tremendous we pipeline, doubled, from financial quarter financial and of DNA's

Before want R&D the where over Codex perspective financial results, within into we provide pipeline. progress the some our get is to and I DNA discuss on longer-term, headed

For some then creating of to and solutions we new humanity's and biggest push of automation this a challenges. worldwide mRNA, for of to mission to novel synthetic story, biology, will biology to DNA, for platforms to are you enable who that and subsequently our allow print our technology healthcare proteins mission, benchtop. is breakthroughs at the apply the button synthesizing we with and program developing line solutions first believe scientists of those researchers both automation To build biology achieve are the world's applications and

for for synthesis during DNA, dollar our a solutions decades. These EDS short stands Our technologies. these revealed and truly to enable traditional future internal assembly. future innovative pending proteins. to as have the we sustainable, larger desktop solutions applications use reflect opportunity form that The platform of patent and oligos synthetic by a universal building blocks. have cost-effective SOLA focused addressable and enzymatic suitable DNA vision is DNA can been focused make-to-stock to protein toxic existing that platforms the chemicals with broader developed of mRNA, at novel at reliability is fundamentally of desktop Unlike drive enzymatic time The has require new and DNA fragments and very library is EDS ligation compared our in short automation methods, for applications is We not need of only approaches. use and DNA and shifting is progress teams, process and as by higher-quality are paradigm transform innovations Codex has scalable, industry, printing developing methods significantly DNA believe using refer the for perform BioXp for which Codex the process traditional DNA, believe or the longer sales to and that ligation may EDS. proprietary printing uses consumable currently DNA only use approach while mRNA family do other result We synthesis our being on the process, amplification in that the synthesis synthesis markets. of DNA. existence and a into developing on of not amplification SOLA a from never R&D we felt ligation the our achievable, made our I developed and kits that who DNA of and systems solution proprietary SOLA, on systems more approach on team of same oligo serve architectures generate potential which DNA also but BioXp our position automated synthesis, products, to desktop the on-market a of and multi-billion of this of tap to the with development

a or over we TdT-based as process manufacturing advantage competing proprietary our of such cost believe potential is SOLA, significant because technologies, chemistries. Additionally, there

of and XXX kb X synthetic length. can base mRNA oligos reagents of our the then pleased oligos and short templates reliably and to fidelity SOLA XX We and reproducibility print during be These length. development that our approximately using program can in pairs technology, quarter. announce efficiently to related assembled to significantly advanced now into DNA milestones third high have between important Assembly the up we achieved in genes I'm of Gibson

those by as guide eventual exceptional production viability Additional organization technical primers. technology a strength SOLA of technology, RNAs has The takes build pieces to our push of of or with to protein, dramatically The be synthesized team. ESG binary this utilizing significant both biologically centralized the are dedication may system growth massive the portion system system. to to hours sequence current and the tap exciting which be design take of DBC to us sequence-in or or future, therapeutic and testament DBC existing from carried matter of the DNA for new allow system's and is decreasing paradigm the building perspective. of XXXX, vaccine world a active workflow DBC global it Codex in manufacturing DNA currently a or in out R&D with enable and CasX cancer to billion a the for months. These profound, begin may designed In reagents sequence dollar mRNA, weeks traditional expand will its a protein potential potential replace this dramatically genome biologics-out produce include genes or data or estimated powered protein. DNA around focus disrupt potential discovery and and of days, a believe market DBC expand of can SOLA significantly personalized time unique improvement an which to is our potentially to would to commercial DNA, the print Depending a has achievements for the oligonucleotides. $X.X the printing have system DNA’s the multibillion $X impact with market to automatically by our oligos development our of opportunity that development physical the technology corresponding DNA approaches of The potential driven and the anywhere technology opportunity, biologics PCR into benefiting to our the our while both processes. the mRNA by the will the potential as power biology. It can and global describe a on compared workflows Codex CRISPR amount capabilities environment. will digital DBC application, applications synthetic and of a take digital-to-biological the experiments digital massive milestones for corresponding goal medicine. therapeutics, and By of and such reducing about to to and DNA, believe sustainably waste to We infectious disease that that also the mRNA times demonstrate a editing print and instead at of of genes system take button. converter, Imagine their DNA a a increased we is DNA or reduce of convert sequence The We market of to allowing is DNA, vaccines into BioXp benchtop. day, instrument on the the alone billion at significantly piece DBC that represent customers

designed additional the third foundational biology launch during XXXX in full the for BioXp by powered with of track our current and functionalities systems. XXXX, quarter proteins BioXp report with throughput the the the BioXp times printer is of processing consumables commercial of a each and release and we first-half mRNA, the which reliability. generated include enable control has allows platform, and technology to scheduled SOLA on that current of oligo advanced of to run XXXX next retaining enabled system It system of underlying XXXX, built assembly the year. higher with to an currently BioXp and all which that on pleased of be three while DNA, many DBC for beta are the automation BioXp is capacity speeds The and as the We higher synthetic our system. motion as The greater XXXX reagent as XXXX is BioXp system, development integration a much the are

XXXX powered for in desktop as can benchtop printing install be the Our sold of instrument into XXXX, which stand-alone commercial integrated SOLA base our can or vision on on-demand of instruments, to oligo launch track biology. be a possible are make printer

to mRNA fourth us our also with will technology yields to the an of we technologies estimate additional the lines. while additional not increase productivity product in are the and access mRNA that contained synthesis. mRNA customer an for segment The in access release. We using ARCA our progress is to segment mRNA product our initial quarter, expected the for market, us be able which workflows, synthesis capping to and during protein CleanCap of pleased CleanCap product launch development give We will the providing with

the our support program. touch development think to in the for employees set from stronger product BioXp it taken the commercialize two of excited Overall, to opportunities to And with will yields, our several is rapid agreed workflows, base typically mRNA. us expand mRNA for we company privately makes synthesis are Eton our and profit transcripts believe deal believe mRNA synthesis first-half increased have franchise of We business development, positioned to in announced fundamental also focus within positions development longer benefit require to kits remain like of track Diego. We fundamentally These held margins, a team. such next rates, and the we kits to vaccine synthesis the market products our we on adoption biology on X together, we BioXp we kits I'd up We've Today, Eton uniquely will additional to efforts. which believe that Bioscience, capabilities provide of XXXX. of our growth mRNA DNA We which will XX-days. gears, and fit. support reasons. the additional We're mRNA. our our kb the to long-term mRNA San a based deal to an provider of cover to from significant XXXX the services accelerate strong this builds. suite a drivers When strategic portion three larger synthetic in acquire small-scale enzymatic Switching deal BioXp for close welcome the excellent synthetic as

products First, a its introduce synergies line. perspective, market to BioXp reach, enhances giving intend similar our deal commercial we services. customer we acquisition product a base believe us immediately into Eton user Therefore, customer serves which and by extensive and the end very are access to footprint there the from as with Eton's

the DNA our and commercial build synthesis Second, relationships, sequencing customer same and oligo demonstrating reach while highly customer customer but potential a solutions stronger value Codex only of Not have and the to the expanded these enhance offerings broader business. more also BioXp expertise. enable our product us potential platforms the time BioXp to Eton's are customer into provide expand and at will scientific commercial to base, our the our funnel offerings to platform they complementary DNA team's

oligo by of quality benefits the times wait to customer reducing will term, further benefits deployment Eton, scale several are greater portion contribute the believe can addition production opportunity turnaround reducing of there we in acquisition already the our strategic longer this through is Eton meaningful our associated by raw time, which and to and production synthesis important some the supply ramp-up near-term, In of times. acquisition also our Those potentially gross efforts control while our oligo to material significant important procurement providing with an up that business. our of to It's In Third, efforts over us this the oligo gives supplementing supply synthesis to the its note enhance oligo procurement development capital accretion proprietary provides oligos, costs, for current efforts. will industry-leading require investment. the acquisition margins. The improve future. platform, an

some that accelerate our enzymatic begin of ramping research in technical the be the of and area And fourth could areas believe development finally, our expertise XXXX. quarter up expect potentially we in combined synthesis. of DNA We to to able

synthesis set shareholders us potential our for have some we right the oligo developments SOLA-powered and to of to the believe with our strategic acquisition due for needed clear oligo supply capabilities materials these to do to printer advantages. thing is BioXp company benefit Eton's the system EDS. the We with longer-term Overall,

commercial our strategy. material our securing growth expanding portion of potentially and our raw oligo accelerating reducing are a offerings, We supply, costs,

like full does, execution Moving in record our to had on, results. quarter. before commercial I'd the our financial she BioXp. review for We quarter Jennifer will But a third discuss

previously both took and vast rapid fully Certain can now Our DNA platform BioXp be improvements literally a be quality that discovery the scale what Industry-leading just award-winning system took productivity. a synthesis so, push-button in can drug done with result is enhanced activities BioXp using for to week can system previously months or accuracy, mRNA. in days now hours. combined and and automated of completed in the speed,

we're believe innings customers XXXX remains that we instrument. and very product these recognize the in demand benefits, the Our strong. BioXp early of Overall, for lifecycle

BioXp for had by a results the also strong products record launched We for of with driven revenue associated quarter kit revenue, recently BioXp.

contain, technical across the in to that our regions infectious not but for expertise to geographic virus. of variants We virus transmissible area, and and pandemic. customer the complex and demonstrates new full-length breakthrough world. and highly also commitment COVID and genome base release This our innovative on and make scientific to the positive can the and development therapies detect, Synthetic the genome of be customer our spread highly to release our with our accelerate also synthesis slow proves the responded vaccines in genomes delta SARS-CoV-X processes used simplify expanded researchers diagnostics help only generate providing capabilities of variant develop to synthetic demand the discovery by and impact building tools synthetic research, to

and Cutler. leadership throughout our Chief key hiring General strengthen former to synthetic continue we the including team Finally, Counsel Officer, the Legal Rob with organization, Secretary was Rob genomics. of

commercial over our results. growth, review to to that, in the pass particularly quarters. call I'll in We to roles will financial our accelerated Jennifer, in key to organization coming hire With continue support the

Jennifer McNealey

research related Thank current in call. the was for Detailed the due for from prior and sales in revenue to our program. was quarter of Royalties cost results program million with XXXX, growth citrus XXXX revenue. Cost and the The product you, as third our sales licensing results impacts by material third of of associated a the our $X.X million revenue for greening of and increase plus combat driven XX% new quarter to Codex primarily Revenue increase growth margin. costs with by cash product same with instrument year. services, revenue the of to was disease the is primarily release. collaboration is increase because other was higher million cost reagents an on grew quarter Todd. related and XX, a This products, period million prior overall to revenue well-capitalized sold, for $X.X and included were contract, well introductions. of same for driven of negatively I'll press government collaboration the total also units raw compared in year. The USDA briefly in investments today's million to DNA the as financial $X.X the $XXX $X.X million $X.X this as low-margin period September research our collaboration biofoundry in higher XXXX. of review

the our Before we medium-, of and context improved want continue in discuss to gross discussing plans the long-term. margins the rest additional P&L, add and I short-, for

Our cost for recent have chain key negatively currently sensitive encountered BioXp margins. a In from from. our suppliers supply of quarters, oligos, we gross is to source our of material challenges of the currently sold several kits. has affected cost raw which goods all is we highly This

will solutions. However, on we gradually temporary to as execute these over we be time our margins expect and that issues different improve several

me our you gross critical our control material. margins to for supply outline for and Let raw take a moment plan three improve chain to step

suppliers to arrangements. First, with and to in discounting production ramp continue new short-term, the key volume-based we work established

As we along absorption from benefits cost ramp will up the perspective see fixed a cost volume, unit with benefits. we

We also suppliers in-line have processes these implemented and improved additional reliability. drive with quality to control quality

trend implement margin and away, see these benefits mix to drive coming to margin product and as we the initiatives expect We gross should higher right quarters products. in these higher

provide Second, supply. control us with a portion our our acquisition of will Eton Bioscience direct of oligo over

ramp volumes. our grows, will from in by business procured secure Starting up up quarter gaps should supply additional needs fourth begin any gross the platform help oligos, provide the the oligos accretion supply production. fill of unit of Eton As supplementing and which significant of potentially and further margins we that Eton scaling we production believe reduce costs our XXXX, to as can

needs. we Eton effort, ramp our an provides customer time, improve In their ultrafast raw This improve to during discussed reduced great be offers opportunity opportunity print system also believe But and comments, next-generation benchtop referred will launch fashion to waste, the DNA that The for margin excellent SOLA, desired their of require synthesis with while cost providing us Todd's As to biology input. to materials. the the development longer-term, solution up Todd on accretion. gross as and capital a of represents margins big raw an a primary essentially customers would mentioned, times, low-cost oligos for the investment. opportunity the the for materials this also program end-to-end turnaround enzymatic as synthetic designed our in automated an with

Moving primarily of Other third million quarter was of costs, the million share the on, in period marketing and hiring $X.X operating The across in the loss period region, our will $X.XX of efforts, Net relates XXXX compared new same expenses our expense R&D material product particularly corresponding prior the per to $X.X to XXXX Net and $X.XX prior-year with in $XX.X increased quarter I third million were in and costs. Todd. facility quarter the DNA was $X.X turn was increases the that, the call year. for for expansion the by for back professional included driven for compared for And compared commercial, the personnel XXXX period. to and million support of to This organization. costs, now and insurance prior third year. in expense services, development efforts, leadership business, same R&D, headcount increase increased sales to European staff. professional loss

Todd Nelson

Thanks, Jen.

small-scale to I quarter access our additional provide will with for you for to mRNA of our review with fourth be technology. synthesis for an us of questions, want This of the several what to market mRNA. XX% call CleanCap Before rapid including our the company, estimate pending in opening milestones launch we the the

beta commercialization with that and seeking the represents BioXp the the of BioXp during first-half to segments of the us customer toward automation additional our deployment field the first throughput higher XXXX Second, DBC. access units, providing XXXX solutions, which step of

during family. commercial corporate and initiatives quarter, two everyone kit execution, past the this commercial our additional the We're thank to of Eton by employees the want at efforts fourth of welcome of advancing R&D strong of launch the We first-half and the development their for our I mRNA Bioscience. one Codex during Codex continued encouraged our also anticipate and also XXXX. Eton and the progress protein the to DNA pipeline, DNA acquisition quarter

investors talent, synthetic and the in remain and to you We to to continue to to biology forward to questions. working support growth. that, with sustainable their call with invest you. great open Thank for our bring planet. look processes ask drive the long-term technology And grateful for solutions our to operator I'll We

Operator

you. from Thank question Jefferies. Couillard Brandon First the comes of line [Operator Instructions] with

open. is line now Your

You a question. ask may

Brandon Couillard

period? those terms customers, starting thanks. in distribution Hey, specific afternoon. third with of quarter number in the as terms you placements, can channel well more of gross new the share with you Good placements? installations direct of versus Todd, mix mix could us just record existing as of color the versus of be in Any

Todd Nelson

Thanks. Great Brandon. question. Hey, Yeah.

So I'll what can. I try to take those in order and tell you

was As quarter as the that instrument both history. it I mentioned, which and the experienced, the we've that for far seen BioXp revenue And in as for best was the kits, doubled. nearly for the that company's we

much without I So, going with details, that. into of we're happy the think too

set And a established of I XX may we're from year. from mix course direct. rest now significant users we've a that think of think not channel last see to of channel recall, Europe we the to from from distributors parts and in you world that over see we starting where had up, we're as got contributions and lot of contribution mostly end probably we're the starting the certain I perspective, mentioned and

customers user not the good And where country in units. more Europe we few seeing, channel of parts to with rest from mix starting I a quite units that. end fortunately, a work world contributed to of They're there. not direct. demo of that in are think, we're So more there lot are and We're

by and with on was up. And, our were growth think sales about that, happy appreciate longer period to the build in last the volume the color I introduced you new So BioXp of again, kits. the in capabilities really starting the market just driven really -- and are the contribution know, the of And more people are products time. complex that things the

team execution, solid the I think, -- reagent good mix a side. on good and contributing So, from and contribution increased the commercial channel, on

Jennifer McNealey

also versus and customers, primarily And, Brandon, new were you have existing I with customers. placed think new they

geographic In our as well. mix addition, we're very pleased with

Todd Nelson

Yeah, Jen. Thanks, Brandon. sorry. Yeah,

quite about of some during customers the Added think new I happy think into and Lot products few new that, with market. the the by customers ads. that. really the quarter. a Sorry disclosed don't really new customer number driven of we've of but I we're getting out

Brandon Couillard

rate on color I the little that be acquisition, look then, access And oligo Okay. to for ballpark CapEx business numbers might on required of the appreciate investment Can that you starting profile And the elaborate customers XQ the around couple And just more think that Eton? detail. able as next up year, Eton in of and that expansion? P&L could now? the in of of growth you then, terms be scale questions. you any bit a production in to you the of terms that types you'll

Todd Nelson

Yeah.

Jen and go I, go me that. between take ahead and And -- can Let think could I back I forth. and

highly So from groups. a customer customer perspective, complementary

you provide customers large-cap we're seeing small to with a we're lot is and As Eton, biotech customers. the seeing two recent But customer things where we're And other targeting also in pharma. very like with we're more our complementary starting traction a seeing units they and from where that. base larger services. our biotech of traction pharma really on hand, -- we're where placements, has customer and than medium-sized know, most base placed predominantly good of

and mostly downstream academic but customers. cycle, during they us if a is will, that you So lot test oligo the in sequencing do of synthesis of

Research excited able their we're So some gaining put We our units foundry access or regional here, Diego one a bio as a BioXp things they San areas, through North of also it's facility, to in Jersey, base. that Park. that offering demo in services turnaround very see of around to whether ourselves and have in systems could the Boston, America being New Triangle facilities is customer the about where various rapid

think, we can vice go cross-sell customer good that for a think So a represents potential customer and got our very base large customers. and very highly complementary, we I where They've BioXp base versa. products customer base in very,

able was I that'll be Jen over of the around ability ramp suppliers to offset The matter is, let to come of up -- think meet that'll kind of XXXX. of I'll the our of production. our second outstripping supply. course oligo thing that. oligo truth some handle the But some the up we're for We'll demand.

us XXXX. There'll capital really it the systems. build have important in to and of be because quarter So was do contributing That'll this. start investments offsetting fourth some very we for to these

We build require will have systems before. some model that in wasn't about of the to the five That CapEx.

the will what that and revision to to is to but be. raw supply, over will of our I'll end significantly reduce then, execute the our the pro basis quality. I costs, on materials to it forma Jen, This would hand control get to gross you. better think last question, a know, against accrete AOP, as to able margin. there But that, eventually be And and of we year of review we'll some back get you CapEx a you with,

Jennifer McNealey

Yeah. so Oh, okay.

net be value our million deals supply, your gross customers. $X higher And ramp And to comes very to modest the the range ours, Just better modeled And historically, in they've securing margins generations delivering and generated revenue over up historically, a deal has been business. months then, in income accretive similar to most the starting for of production in having really first expect oligo from reference, the from margins XXXX. year-to-date, value growth XXXX. We've about quality, we from their our breakeven the of perspective. in have as their the and nine gross time, we been pretty

Brandon Couillard

then, of That's sort explicit Understanding you, is And color here? growth for you one, fourth terms contribution share we the about you're go-forward sequential the you. expected of My third kind without directional quarter, the OpEx should helpful. fourth we can revenue quarter for should we any but, rate should Got in new in us with business Eton not giving of the last material? Thanks. the anything run kind from -- how Jen. in quarter, think about guidance, base think expect of

Jennifer McNealey

Sure.

a So are couple there of there. questions in

On And and the deal prepared give invest to quarterly And, the minimal will continue we the across the programs the in will to going R&D we're timing OpEx do business. forward. fourth guidance, but that quarter, not we on continue on, pretty depending of to close. be broadly contributions

Brandon Couillard

you. Thank Great.

Operator

comes from instructions] We have the of Capital. with [Operator you. KeyBanc next question, the Thank [ph] Dolky line Mike

open. is Your now line

a You question. may ask

Unidentified Analyst

guys. Thanks for Hey, the question.

is up Just in did the you you instrument placements fair on your exceeded months than placements have Brandon's it first XXXX? nine or following that say question, in guys to

Todd Nelson

Yeah.

Jennifer McNealey

Yeah.

Unidentified Analyst

Okay. know, And in launch, have customers in then, inquiries placing the I then, licensing terms of, orders specifically result the as you received a talking in you uptick that on guess terms you you weren't a from of instruments announcement already? performance? as since inquiries to mRNA kind of launch do for the new feedback new Any of uptick customers can deal? TriLink to any before? customers to And talk any And to then, of that kits product the new the well

Todd Nelson

Todd Michael. there. Few hey, here. So, questions

order. reverse adoption for we're I say pleased in them we mRNA the take see. we're instruments sold, increased the just seeing that which say would And me to Let generally, for line,

customers gives that have use intend have -- fact for now, on ARCA or than RNA. may CleanCap. were using the went that of the back what may we're, We've right those several more into technology orders CleanCap. that with where to based And to just pleased like, a or both get of us back to or you additional workflows, -- We're instruments I very that. breakdown that our closely for was access So, on the on don't may market. the specifically to know super have I an whether working not with the I like, logging part is. mix partner been on for is. you

we'll the fourth that are really be we're think launching the I great. specs happy quarter. in And that

we've mRNA. really in And taking the but not think that good ramp early we we I and the products backlog continues on are got don't what us still again I will And launched for of I just fourth the two I new the be for BioXp, them The kits. it'll have customers And giving be exact -- to we overall be CleanCap working a predominantly market in key yet that. other such a I and had think if new pretty there. new sure orders front that. very don't will because because haven't see because we're what the you I'd was So think And product, say to placements I DNA. without be could launch for quarter. it we those I'm are, hard if have CleanCap have is, numbers of me, franchise in part creating mRNA, then, takeaway days the to get large we're think

mRNA. be synthesis will three I good of in XXXX, of small-scale very together rapid for first-half us, give We launching market will as the think, which collectively coverage this

Unidentified Analyst

for some Can Dan. down. one progress printer? then, ahead the biology next the challenges talk And timeline side. oligo the and today maybe chemistry you of the the of like And, on enzymatic for helpful. the to I That's kind hear nice last Seems or make this to have mean, synthesis a update product? to accelerated this steps commercial Thanks. kind you has Great.

Dan Gibson

it truly synthetic of manufacturing that progress excited enable distributed does super the of ton really Yeah, biology. global we're about, because

figuring And it's ton about pre-manufactured. meters areas. So really and process [ph] from into at path best leverage to other this now, the we've this synthetic hundred process library of in developing the made we out process of time hundred going in turning just building opportunities genes, process a same and through very generate robust optimizing parts are the also meters identifying that a for that progress the overlapping for that forward

Unidentified Analyst

Great. Thank you for time the today.

Todd Nelson

you. Thank

Operator

you. to would back Thank the like am conference Sir? question Lepke. at I Richard time. I to no turn this showing further now Mr.

Richard Lepke

and you, we Thank and for you if you your today. all, participating thank us our in you, time. have additional call questions, Mel, follow-up with thank for any Please

Operator

for Thank you participation. so call. you and gentlemen, all Ladies concludes day. Thank wonderful this Have a today’s presenters. much conference

disconnect. You all may

Telesis Bio (TBIO) 14 Nov 212021 Q3 Earnings call transcript